$1.61 EPS Expected for IBERIABANK (IBKC); First Commonwealth Financial Has Raised By $482,769 Its Bristol Myers Squibb Co (BMY) Stake

June 19, 2018 - By Louis Casey


First Commonwealth Financial Corp increased Bristol Myers Squibb Co (BMY) stake by 211.8% reported in 2018Q1 SEC filing. First Commonwealth Financial Corp acquired 7,663 shares as Bristol Myers Squibb Co (BMY)’s stock declined 23.11%. The First Commonwealth Financial Corp holds 11,281 shares with $714,000 value, up from 3,618 last quarter. Bristol Myers Squibb Co now has $87.69 billion valuation. The stock decreased 2.10% or $1.15 during the last trading session, reaching $53.65. About 8.52M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 2.98% since June 19, 2017 and is downtrending. It has underperformed by 15.55% the S&P500. Some Historical BMY News: ; 26/04/2018 – Bristol-Myers Raises 2018 View To Adj EPS $3.35-Adj EPS $3.45; 26/04/2018 – Rhode Island DoA: Bristol Fourth of July Committee Thu, 4/26/2018, 8:30 PM; 26/04/2018 – ROCHE HOLDING AG ROG.S SAYS TECENTRIQ SALES 139 MLN SFR VS RTRS POLL AVG 154 MLN SFR; 09/04/2018 – STAT Plus: With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies; 03/04/2018 – NEKTAR: BMY MADE UPFRONT CASH PAYMENT OF $1.0B TO NEKTAR; 06/03/2018 – FDA approves new dosing for Bristol-Myers Squibb’s Opdivo; 25/05/2018 – IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non; 16/04/2018 – Heard on the Street: Bristol-Myers has Farther to Fall; 18/05/2018 – 5.1 MAG. EARTHQUAKE 166KM S OF BRISTOL ISLAND SOUTH SANDWICH; 16/04/2018 – Most interesting data point in $BMY CM-227 PR Opdivo monotherapy failed in high TMB ≥13 mut/Mb and ≥1% positive PD-L1 expression PFS HR 0.95; p=0.7776

Analysts expect IBERIABANK Corporation (NASDAQ:IBKC) to report $1.61 EPS on July, 19.They anticipate $0.51 EPS change or 46.36% from last quarter’s $1.1 EPS. IBKC’s profit would be $91.21 million giving it 12.52 P/E if the $1.61 EPS is correct. After having $1.37 EPS previously, IBERIABANK Corporation’s analysts see 17.52% EPS growth. It closed at $80.65 lastly. It is down 2.46% since June 19, 2017 and is uptrending. It has underperformed by 10.11% the S&P500. Some Historical IBKC News: ; 19/04/2018 – Correct: Iberiabank Sets 2020 Goal for Core EPS Growth Above 10%; 23/03/2018 – IBERIABANK Corporation Completes Acquisition Of Gibraltar Private Bank & Trust Co; 19/04/2018 – Iberiabank Sets 2020 Goal for 10% EPS Growth; 22/03/2018 – IBERIABANK RELEASE 2020 STRATEGIC GOALS ON APRIL 19; 11/05/2018 – EJF Capital Adds Taylor Morrison, Exits Iberiabank: 13F; 19/04/2018 – IBERIABANK REAFFIRMS FORECAST FOR 2018; 18/05/2018 – IBERIABANK REPORTS BRANCH CLOSURES & CONSOLIDATIONS; 18/05/2018 – IBERIABANK: 22 Branches to Be Closed or Consolidated Are Incremental to Branch Consolidations Already Planned; 18/05/2018 – IBERIABANK WILL CLOSE OR CONSOLIDATE 22 BRANCHES IN 2Q, 3Q; 23/04/2018 – DJ IBERIABANK Corporation, Inst Holders, 1Q 2018 (IBKC)

Among 14 analysts covering IberiaBank (NASDAQ:IBKC), 9 have Buy rating, 0 Sell and 5 Hold. Therefore 64% are positive. IberiaBank had 57 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of IBERIABANK Corporation (NASDAQ:IBKC) earned “Market Outperform” rating by JMP Securities on Tuesday, July 25. The firm earned “Buy” rating on Monday, June 5 by Keefe Bruyette & Woods. Jefferies maintained it with “Buy” rating and $96.0 target in Monday, January 8 report. Keefe Bruyette & Woods maintained IBERIABANK Corporation (NASDAQ:IBKC) on Thursday, December 21 with “Buy” rating. The firm has “Hold” rating by Robert W. Baird given on Monday, October 23. The stock of IBERIABANK Corporation (NASDAQ:IBKC) has “Buy” rating given on Monday, January 29 by Keefe Bruyette & Woods. FBR Capital initiated IBERIABANK Corporation (NASDAQ:IBKC) on Thursday, March 31 with “Outperform” rating. The firm has “Neutral” rating by Piper Jaffray given on Thursday, January 7. The stock of IBERIABANK Corporation (NASDAQ:IBKC) has “Buy” rating given on Wednesday, December 20 by SunTrust. The company was downgraded on Wednesday, March 1 by Piper Jaffray.

IBERIABANK Corporation operates as the bank holding firm for IBERIABANK that provides commercial and retail banking services and products in the United States. The company has market cap of $4.57 billion. It offers various commercial, consumer, mortgage, and private banking services and products; cash management services; deposit and annuity products; and brokerage services, as well as sells variable annuities. It has a 29.4 P/E ratio. The firm also provides various title insurance and loan closing services for residential and commercial customers; one-to-four family residential mortgage loans; equity research, institutional sales and trading, and corporate finance services; and wealth management and trust advisory services to high net worth individuals, pension funds, firms, and trusts, as well as invests in a commercial rental property and purchased tax credits.

Investors sentiment decreased to 1.12 in Q1 2018. Its down 0.04, from 1.16 in 2017Q4. It dropped, as 16 investors sold IBERIABANK Corporation shares while 73 reduced holdings. 32 funds opened positions while 68 raised stakes. 44.08 million shares or 2.56% less from 45.24 million shares in 2017Q4 were reported. Jane Street Grp Incorporated Ltd Liability Corp reported 4,337 shares. Rhumbline Advisers holds 0.01% of its portfolio in IBERIABANK Corporation (NASDAQ:IBKC) for 52,790 shares. 4,524 were reported by Us Bank De. Bluemountain Mgmt Limited Company, a New York-based fund reported 637 shares. Stieven Cap Advsrs Limited Partnership holds 1.52% or 122,800 shares in its portfolio. Communication Of Vermont holds 0% of its portfolio in IBERIABANK Corporation (NASDAQ:IBKC) for 36 shares. Morgan Stanley reported 164,920 shares. State Street holds 2.78 million shares. Moreover, Stevens Cap Limited Partnership has 0.02% invested in IBERIABANK Corporation (NASDAQ:IBKC). Sterling Cap Mgmt Ltd Liability holds 0.2% of its portfolio in IBERIABANK Corporation (NASDAQ:IBKC) for 275,250 shares. Balyasny Asset Mngmt Ltd holds 258,797 shares or 0.08% of its portfolio. Raymond James Financial Service Advsrs Inc owns 39,363 shares. The Ontario – Canada-based Canada Pension Plan Inv Board has invested 0.01% in IBERIABANK Corporation (NASDAQ:IBKC). Tiaa Cref Invest Mgmt Limited Liability Company invested 0.01% in IBERIABANK Corporation (NASDAQ:IBKC). Silvercrest Asset Gru Limited reported 2.80 million shares.

More news for IBERIABANK Corporation (NASDAQ:IBKC) were recently published by: Seekingalpha.com, which released: “IBERIABANK announces branch closures and consolidations” on May 21, 2018. Equitiesfocus.com‘s article titled: “Iberiabank (NASDAQ:IBKC) is Silvercrest Asset Management Group LLC’s Largest Position” and published on June 18, 2018 is yet another important article.

Since June 6, 2018, it had 0 buys, and 1 sale for $98,460 activity. $98,460 worth of IBERIABANK Corporation (NASDAQ:IBKC) was sold by BREAUX ERNEST P JR.

Since April 30, 2018, it had 1 buy, and 0 insider sales for $249,948 activity. $249,948 worth of Bristol-Myers Squibb Company (NYSE:BMY) was bought by Paliwal Dinesh C.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 2 Sell and 14 Hold. Therefore 27% are positive. Bristol-Myers Squibb Company had 87 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Credit Suisse on Monday, May 9. Cowen & Co maintained Bristol-Myers Squibb Company (NYSE:BMY) on Monday, July 10 with “Hold” rating. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Buy” rating by Berenberg on Friday, January 22. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Buy” rating by UBS on Friday, August 19. The firm has “Hold” rating given on Monday, October 16 by Jefferies. The firm has “Hold” rating by Berenberg given on Thursday, August 11. Jefferies maintained Bristol-Myers Squibb Company (NYSE:BMY) on Monday, July 17 with “Buy” rating. Piper Jaffray maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, September 22 with “Hold” rating. BMO Capital Markets maintained it with “Underperform” rating and $47 target in Wednesday, April 18 report. The rating was initiated by Atlantic Securities on Friday, December 18 with “Underweight”.

Investors sentiment decreased to 0.83 in 2018 Q1. Its down 0.11, from 0.94 in 2017Q4. It is negative, as 64 investors sold BMY shares while 573 reduced holdings. 111 funds opened positions while 418 raised stakes. 1.12 billion shares or 1.08% more from 1.11 billion shares in 2017Q4 were reported. Dimensional Fund Advsrs Lp has invested 0.1% in Bristol-Myers Squibb Company (NYSE:BMY). Bowen Hanes holds 10,805 shares. Holderness Investments Communications accumulated 26,125 shares. Utd Asset Strategies Inc holds 4,602 shares or 0.09% of its portfolio. Joel Isaacson Ltd Llc owns 14,356 shares or 0.16% of their US portfolio. Millennium Management Ltd Limited Liability Company reported 2.73 million shares. 11,975 were accumulated by Mutual Of Omaha Bancshares Wealth. Auxier Asset has 7,393 shares. Optimum Investment invested in 57,009 shares or 1.06% of the stock. Alpha Cubed Limited Liability Co holds 10,020 shares or 0.08% of its portfolio. Smith Moore And has invested 0.32% in Bristol-Myers Squibb Company (NYSE:BMY). Glob X Management Ltd Llc, a New York-based fund reported 7,049 shares. Essex Investment Management Ltd stated it has 0.1% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Ftb Advsrs reported 0.07% in Bristol-Myers Squibb Company (NYSE:BMY). Alphamark Advsr Llc reported 0.02% in Bristol-Myers Squibb Company (NYSE:BMY).

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Bristol-Myers Top NASH Contenders” on June 12, 2018, also Seekingalpha.com with their article: “Neon Therapeutics readies IPO” published on June 01, 2018, Seekingalpha.com published: “Merck up 2% premarket on positive Keytruda data; Bristol-Myers down 2%” on June 04, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Bristol-Myers Squibb (BMY) Presents at UBS Global Healthcare Conference (Transcript)” published on May 22, 2018 as well as Streetinsider.com‘s news article titled: “Bristol-Myers Squibb (BMY) Says China National Drug Administration Approved Country’s First Immuno-Oncology …” with publication date: June 15, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts